New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant Voyager’s wholly-owned Alzheimer’s disease franchise now includes clinical-stage anti-tau antibody VY7523 as well as gene therapies targeting tau, amyloid, and APOE LEXINGTON, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc.... Read More